Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin

Empagliflozin (EMPA) is a sodium–glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases. However, the possible benefits and mechanisms of its antiarrhythmic effects in cardiac ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhuo, Shih-Jie, Liu, I-Hsin, Tasi, Wei-Chung, Chou, Te-Wu, Lin, Yi-Hsiung, Wu, Bin-Nan, Lee, Kun-Tai, Lai, Wen-Ter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200966/
https://www.ncbi.nlm.nih.gov/pubmed/34198942
http://dx.doi.org/10.3390/ijms22116105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200966/
https://www.ncbi.nlm.nih.gov/pubmed/34198942
http://dx.doi.org/10.3390/ijms22116105

Ejemplares similares